Fate Therapeutics, Inc. (FATE)

Fate Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	486	369	980	5,587	7,933	1,479
Market Cap Growth	30.18%	-62.39%	-82.45%	-29.57%	436.26%	78.71%
Enterprise Value	189	142	638	5,071	7,532	1,285
PE Ratio	-	-2.29	-3.48	-26.34	-45.75	-15.07
PS Ratio	75.03	5.80	10.18	100.05	252.37	138.52
PB Ratio	1.14	1.00	2.03	8.23	20.64	6.04
P/FCF Ratio	-5.21	-2.66	-3.46	-26.16	-179.64	-16.33
P/OCF Ratio	-5.33	-2.79	-3.95	-34.31	-202.23	-17.79
EV/Sales Ratio	29.24	2.23	6.63	90.80	239.62	120.28
EV/EBITDA Ratio	-2.52	-1.00	-2.38	-24.58	-44.23	-13.64
EV/EBIT Ratio	-2.27	-0.88	-2.27	-23.90	-43.44	-13.33
EV/FCF Ratio	-3.09	-1.03	-2.25	-23.74	-170.56	-14.18
Debt / Equity Ratio	0.24	0.28	0.23	0.17	0.25	0.11
Debt / EBITDA Ratio	-0.60	-0.73	-0.41	-0.56	-0.57	-0.29
Debt / FCF Ratio	-0.73	-0.75	-0.39	-0.54	-2.20	-0.30
Quick Ratio	8.81	8.50	4.30	7.87	5.89	7.97
Current Ratio	8.69	8.48	4.40	7.79	5.78	8.17
Asset Turnover	0.01	0.11	0.12	0.06	0.06	0.04
Interest Coverage	-	-	-	-	-	-55.02
Return on Equity (ROE)	-46.50%	-38.20%	-50.90%	-28.80%	-46.20%	-49.90%
Return on Assets (ROA)	-34.50%	-28.40%	-36.10%	-21.40%	-31.20%	-36.90%
Return on Capital (ROIC)	-40.32%	-40.37%	-51.98%	-27.34%	-26.59%	-37.08%
Earnings Yield	-39.10%	-43.64%	-28.73%	-3.80%	-2.19%	-6.63%
FCF Yield	-28.76%	-37.53%	-28.94%	-3.82%	-0.56%	-6.12%
Buyback Yield / Dilution	-3.11%	-1.64%	-2.19%	-15.01%	-20.82%	-21.35%
Total Shareholder Return	-3.11%	-1.64%	-2.19%	-15.01%	-20.82%	-21.35%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).